NEW YORK , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and
NEW YORK , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq: ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $29.50 per share.
NEW YORK , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced that it has commenced an underwritten public offering of 10,000,000 shares of its common stock. In connection with the offering, Intra-Cellular Therapies intends
NEW YORK , Jan. 02, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled
NEW YORK , Dec. 23, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA ® (lumateperone) has been approved by the U.S.
Bipolar depression: Study 404, A Phase 3 Clinical Trial of lumateperone for the treatment of Bipolar Depression, investigating the potential of lumateperone as a new option for the treatment of depressive episodes in patients suffering from Bipolar I or Bipolar II disorder. Schizophrenia:
NEW YORK , Dec. 04, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the Company will be presenting at the 58th Annual Meeting of the
NEW YORK , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today provided a corporate update and announced its financial results for the third quarter
NEW YORK , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m.
NEW YORK , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled
Data indicate ITI-214 at a dose of 30 mg is well tolerated with a favorable safety profile Study ‘104 now proceeding to a third cohort at a dose of 90 mg NEW YORK , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI) today announced the successful completion of the
FDA has informed the Company it has no plans to schedule an Advisory Committee Meeting Company has completed submission of non-clinical information previously agreed with FDA NEW YORK , Sept. 10, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company
NEW YORK , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today provided a corporate update and announced its financial results for the second quarter
NEW YORK , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled
Agreement reached with FDA on submission of additional non-clinical information for NDA review of lumateperone for the treatment of schizophrenia Lumateperone PDUFA goal date extended three months to December 27, 2019 Conference call scheduled today at 8:30 am ET NEW YORK , Aug.